ADC Therapeutics SA (ADCT)
NYSE · Manufacturing · Pharmaceutical preparations
ADCT price, last 12 months
Key stats
- Previous close
- $1.29
- Open
- $1.26
- Day range
- $1.21 – $1.29
- 52-week range
- $0.7796 – $4.98
- Volume
- 1.1M
- Avg volume (20 days)
- 1.6M
- Market cap
- $162.1M
Performance
Technicals and fundamentals
About ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NYSE
- Market cap
- $162.1M